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Abstract 
Background: With increasing concern about the environmental impact of a petroleum based economy, focus has 
shifted towards greener production strategies including metabolic engineering of microbes for the conversion of 
plant-based feedstocks to second generation biofuels and industrial chemicals. Saccharomyces cerevisiae is an attrac-
tive host for this purpose as it has been extensively engineered for production of various fuels and chemicals. Many of 
the target molecules are derived from the central metabolite and molecular building block, acetyl-CoA. To date, it has 
been difficult to engineer S. cerevisiae to continuously convert sugars present in biomass-based feedstocks to acetyl-
CoA derived products due to intrinsic physiological constraints—in respiring cells, the precursor pyruvate is directed 
away from the endogenous cytosolic acetyl-CoA biosynthesis pathway towards the mitochondria, and in fermenting 
cells pyruvate is directed towards the byproduct ethanol. In this study we incorporated an alternative mode of acetyl-
CoA biosynthesis mediated by ATP citrate lyase (ACL) that may obviate such constraints.
Results: We characterized the activity of several heterologously expressed ACLs in crude cell lysates, and found that 
ACL from Aspergillus nidulans demonstrated the highest activity. We employed a push/pull strategy to shunt citrate 
towards ACL by deletion of the mitochondrial NAD+-dependent isocitrate dehydrogenase (IDH1) and engineer-
ing higher flux through the upper mevalonate pathway. We demonstrated that combining the two modifications 
increases accumulation of mevalonate pathway intermediates, and that both modifications are required to substan-
tially increase production. Finally, we incorporated a block strategy by replacing the native ERG12 (mevalonate kinase) 
promoter with the copper-repressible CTR3 promoter to maximize accumulation of the commercially important 
molecule mevalonate.
Conclusion: By combining the push/pull/block strategies, we significantly improved mevalonate production. We 
anticipate that this strategy can be used to improve the efficiency with which industrial strains of S. cerevisiae convert 
feedstocks to acetyl-CoA derived fuels and chemicals.
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Background
Increasing environmental concerns about the sustain-
ability of producing petroleum-derived chemicals has led 
to increased interest in alternative means of production. 
Metabolic engineering of microorganisms to convert bio-
mass and organic waste to chemicals that are ordinarily 
derived from petroleum represents a more sustainable 
production strategy. The yeast Saccharomyces cerevi-
siae is a commonly used microbial cell factory for meta-
bolic engineering [2, 3, 28] as it is tolerant of industrial 
conditions, is extraordinarily well-characterized, and 
offers tools for genetic engineering [19, 20, 29]. While 
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an immense amount of progress has been made, there 
remains room to improve the efficiency with which engi-
neered microbes produce chemicals from feedstocks.
Acetyl-CoA is a key molecule in central carbon metab-
olism [23], as it is required for basic cellular functions 
such as energy metabolism, lipid metabolism, and amino 
acid metabolism. Acetyl-CoA also serves as a precur-
sor for the biosynthesis of many industrial chemicals 
including lipids (dietary supplements and biodiesels), 
polyketides (antibiotics and anticancer drugs), polyhy-
droxyalkanoates (biodegradable polymers), and isopre-
noids (flavors and fragrances, biodiesels, anti-microbials 
and anti-cancer drugs, rubber, cosmetic additives and 
vitamins). In addition, the isoprenoid pathway interme-
diate mevalonate has been cited for its use as a precur-
sor for biobased production of β-methyl-δ-valerolactone, 
which can be transformed into a rubbery polymer [42].
In S. cerevisiae, cytoplasmic acetyl-CoA is endoge-
nously produced from pyruvate through three metabolic 
steps called the pyruvate dehydrogenase (PDH) bypass. 
However, due to the nature of the endogenous regula-
tory metabolism, production of acetyl-CoA  derived 
metabolites via the native cytoplasmic PDH bypass is 
constrained: when grown at high glucose concentrations 
a significant portion of glucose is converted to reduced 
byproducts such as ethanol [41], whereas at low glucose 
concentrations the bulk of pyruvate is transported to the 
mitochondria [32].
Once pyruvate enters the mitochondrion it can be con-
verted to acetyl-CoA by the PDH complex, however, this 
mitochondrial acetyl-CoA pool is not available to cyto-
plasmic biosynthesis pathways.
Although a transport mechanism for shuttling acetyl-
CoA from the mitochondrion to the cytoplasm does not 
exist in S. cerevisiae, many other organisms shuttle acetyl-
CoA through the intermediate citrate. This is typified by 
oleaginous yeast species, which are defined by their abil-
ity to accumulate high levels of cytoplasmic acetyl-CoA 
derived triacylglycerides in nitrogen-limiting conditions 
[33, 34]. At the genomic level, a key characteristic of ole-
aginous yeasts is that they contain genes encoding the 
ATP citrate lyase (ACL), whereas non-oleaginous yeasts 
such as S. cerevisiae do not [1]. It has been demonstrated 
that in low nitrogen conditions, inhibition of isocitrate 
dehydrogenase (ICDH) leads to citrate accumulation, 
cytosolic transport, and cleavage by ACL thus generating 
cytoplasmic acetyl-CoA [9, 10] (Fig. 1).
In this study, we reconstituted the salient features of 
the ACL pathway in S. cerevisiae through genetic engi-
neering and media optimization. As a proof of principle, 
we demonstrate that this alternative mode of metabo-
lism can be used to significantly increase the yield of the 
acetyl-CoA derived product mevalonate. E. coli has also 
been engineered to produce mevalonate as a final prod-
uct [42]. While the mevalonate pathway in S. cerevisiae 
has been extensively engineered to produce various iso-
prenoid products, this is the first study to our knowledge, 
to produce mevalonate as a final product.
Methods
Media, cultivation, and transformation
For strain construction, pre-cultures were grown with 
5  mL of Yeast extract  +  Peptone  +  Dextrose (YPD) 
medium in glass test tubes with shaking at 200  rpm. 
After 18 h of growth, pre-cultures were used to inoculate 
50-mL cultures in 250-mL Erlenmeyer flasks. After ~6 h 
of growth, strains were transformed by the lithium ace-
tate method [14]. For construction of IDH1::HygB, the 
Hygromycin B resistance cassette was amplified from 
pUG32 [15] with primers containing 40 base pairs cor-
responding to the chromosomal sequence immediately 
5′ and 3′ of the IDH1 locus. For construction of strains 
containing integrated heterologous gene sequences, the 
integration fragments were amplified from their cor-
responding plasmids (Additional file  1: Table S1). Each 
integration fragment contained the heterologous genes 
and either an auxotrophic complementation or drug 
resistance cassette, with flanking 750 base pairs cor-
responding to the site of chromosomal integration. To 
select for DNA transformants containing auxotrophic 
complementation cassettes, cells were plated on stand-
ard dropout medium (Sunrise, San Diego), and for DNA 
transformants containing drug resistance cassettes, cells 
were plated on YPD, grown for 24  h, and then replica 
plated to YPD supplemented with 200  μg/L Geneticin 
(Sigma, cat. no. A1720) or Hygromycin B (Sigma, cat. no. 
H7772).
For the ACL activity assay, single colonies were used to 
inoculate 5 mL Yeast extract + Peptone (YP) + 2 % galac-
tose liquid cultures. Cultures were then diluted into fresh 
medium to an OD of 0.05, and grown for 24 h.
For metabolomics and production experiments, strains 
were grown at 30  °C with shaking at 200  rpm in a base 
medium composed of 6.7 g/L Yeast Nitrogen Base (YNB) 
without amino acids, without ammonium sulfate (Difco), 
and 0.7  g/L Complete Supplemented Media (CSM) 
amino acid mixture (Sunrise, San Diego). Media were 
supplemented with additional components as specified 
below. For metabolomics quantification, cultures were 
grown in the base medium supplemented with 2  % raf-
finose and 0.1  % dextrose. Five milliliter pre-cultures 
were inoculated from single colonies and grown for 36 h 
in test tubes. Production cultures (50 mL) supplemented 
with 2 % galactose were inoculated to an initial OD600 of 
0.05 in 250-mL Erlenmeyer flasks. Low nitrogen cultures 
were supplemented with 7 mg/L ammonium sulfate, and 
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standard nitrogen cultures were supplemented with 1 g/L 
ammonium sulfate.
For experiments ‘Increasing pull on cytoplasmic acetyl-
CoA towards the mevalonate pathway,’ 10-mL pre-cul-
tures supplemented with 2  % galactose were grown for 
36  h in test tubes. These cultures were used to inocu-
late an additional 10-mL pre-culture to an initial OD600 
of 0.2, which was grown for 6  h. The resulting cultures 
were centrifuged at 3000×g and washed once with fresh 
base medium. A fraction of the resulting cell suspension 
was centrifuged and resuspended in 10 mL of fresh base 
medium in test tubes so as to reach an initial OD600 of 
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Fig. 1 Diagram of S. cerevisiae metabolic pathways relevant to this study. Engineered enzymatic steps of native yeast metabolism are IDH1, isoci-
trate dehydrogenase 1 and ERG12, mevalonate kinase. Non-native engineered enzymatic steps are ACL, ATP citrate lyase of Aspergillus nidulans; 
mvaE acetoacetyl-CoA synthase and HMG-reductase of Enterococcus faecalis; mvaS, acetoacetyl-CoA thiolase of Enterococcus faecalis
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Gene synthesis
Coding sequences for ACLa and ACLb from Aspergil-
lus nidulans were obtained from the Aspergillus Com-
parative Database (http://www.broadinstitute.org/
annotation/genome/aspergillus_group). Both genes were 
codon optimized for S. cerevisiae and synthesized by Gen-
script (Piscataway, New Jersey). The genes were cloned 
into pADS-AMO-CPR [35] to generate JBEI-7134. Addi-
tional ACL coding sequences were obtained at the fol-
lowing locations: the Rhodosporidium toruloides gene 
was obtained from the Genomics Web Portal (http://
crdd.osdd.net/raghava/genomesrs/); the Yarrowia lipo-
lytica genes were obtained from the Genelovures Yeast 
Genomes Database (http://genolevures.org/yali.html); 
the Lipomyces starkeyi genes were obtained from the JGI 
Genome Portal (http://genome.jgi.doe.gov/Lipst1_1/
Lipst1_1.home.html); and the Mus musculus gene was 
obtained from the NCBI Gene Database (http://www.ncbi.
nlm.nih.gov/gene/104112). Coding sequences were opti-
mized for expression in S. cerevisiae using the IDT codon 
optimization tool, and were cloned into the pESC-LEU2d 
(strain  Keasling-1951) parent plasmid by JGI to generate 
JBEI-10648, and JBEI-10641–10644 (see Table 1).
MvaE was codon optimized for S. cerevisiae and syn-
thesized by Genscript (Piscataway, New Jersey). The 
coding sequences were obtained from NCBI cataloged 
under accession: AF290092.1 GI: 9937382. MvaS was 
amplified directly from the Enterococcus faecalis genome, 
with primers designed to amplify from the nucleo-
tide sequence obtained from the same NCBI accession 
number.
Plasmid construction
All strains (Table  1), expression plasmids (Table  2), 
additional plasmids used for constructing strains and 
expression plasmids (Additional file  1: Table S1), and 
the corresponding sequence files are described in the 
JBEI Public Registry (https://public-registry.jbei.org/) 
[16], and are available upon request. All plasmids built 
in this study used for strain and expression plasmid con-
struction were constructed using Gibson assembly [13] 
or Yeast assembly [27]. Plasmids were designed using 
Device Editor bioCAD software [4], and assembly prim-
ers were generated with j5 DNA assembly design auto-
mation software [18] using the default settings. PCR 
amplification was performed using Prime STAR GXL 
DNA polymerase using the manufacturer’s instructions 
(Takara). Assemblies were performed using Gibson 
assembly master mix (New England Biolabs), and were 
transformed into DH10b competent cells for propaga-
tion. Plasmid DNA was purified using a QIAprep Spin 
Miniprep Kit (QIAGEN), and plasmids were sequenced 
with  ~2X coverage (Quintara). DNA sequences derived 
from S. cerevisiae were amplified from genomic DNA 
prepared using a modified Miniprep protocol: 1 mL yeast 
cell culture in YPD medium was centrifuged in a screw 
cap tube (3000×g) and resuspended in buffer P1 (from 
Qiagen kit). Cells were lysed by adding glass beads and 
shaking in a benchtop homogenizer/bead beating instru-
ment (FastPrep-24, MP Biomedicals) for ~1 min. Result-
ing suspension was used for remaining steps in Qiagen 
Miniprep protocol. Details of construction for each plas-
mid are as follows:
Table 1 Strains and plasmids
Yeast strains used in this study
Strain Genotype Reference
BY4741 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 Euroscarf
JBEI-10683 BY4741 ura3::PGAL10-AnACLb-PGAL1-AnACLa-kanMX4 This study
JBEI-10684 BY4741 ura3::PGAL1-RtACL-kanMX4 This study
JBEI-10685 BY4741 ura3::PGAL1-MmACL-kanMX4 This study
JBEI-10686 BY4741 ura3::PGAL10-YlACLb-PGAL1-YlACLa-kanMX4 This study
JBEI-10687 BY4741 ura3::PGAL10-LsACLb-PGAL1-LsACLa-kanMX4 This study
JBEI-10688 BY4741 idh1::kanMX4 Euroscarf
JBEI-10689 BY4741 ura3::PGAL10-AnACLb-PGAL1-AnACLa-kanMX4 idh1::hphMX4 This study
JBEI-10569 BY4741 trp1::EfMvaE-EfMvaS–SpHIS5 This study
JBEI-10690 BY4741 ura3::PGAL10-AnACLb-PGAL1-AnACLa-kanMX4 trp1::EfMvaE-EfMvaS–SpHIS5 This study
JBEI-10691 BY4741 ura3::PGAL10-AnACLb-PGAL1-AnACLa-kanMX4 idh1::hphMX4 trp1::EfMvaE-EfMvaS–SpHIS5 This study
JBEI-10692 BY4741 ura3::PGAL10-AnACLb-PGAL1-AnACLa-kanMX4 idh1::ylIDH–CaURA3 trp1::EfMvaE-EfMvaS–SpHIS5 This study
JBEI-10693 BY4741 ura3::PGAL10-AnACLb-PGAL1-AnACLa-kanMX4 idh1::hphMX4 ERG12::KlLeu2–PCTR3-ERG12 This study
JBEI-10694 BY4741 ura3::PGAL10-AnACLb-PGAL1-AnACLa-kanMX4 ERG12::KlLeu2–PCTR3-ERG12 This study
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JBEI-7134 (pACLab). Two multi-copy plasmids, 
pRS426 [5] and pESC-URA (Stratagene, La Jolla), were 
previously combined to form plasmid pADS-AMO-CPR 
[35]. This plasmid contained genes encoding amorphadi-
ene synthase (ADS), amorphadiene oxidase (AMO) and 
its redox partner cytochrome P450 reductase (CPR). We 
removed the AMO and CPR genes and replaced them 
with ACLa and ACLb genes, respectively, to form pESC-
PGAL1ACLa-PGAL10ACLb-PGAL1-ADS-LEU2d (JBEI-3271) 
plasmid. Then ADS was removed by yeast homologous 
recombination. Phosphorylated primers, with 20 over-
hanging base pairs and matching ends homologous 
to the promoter or terminator regions surrounding 
ADS, were designed to amplify the pESC-PGAL1ACLa-
PGAL10ACLb-PGAL1-ADS-LEU2d vector regions sur-
rounding the ADS gene by PCR. The PCR product was 
transformed into yeast and colonies were screened for 
the removal of ADS by PCR. The resulting construct was 
purified using a modified Miniprep protocol (described 
above) and transformed into DH10b competent cells for 
propagation.
JBEI-10632 (pMvaES). This plasmid was constructed 
from Keasling-2159 by replacing AMO with mvaE and 
CPR with mvaS using standard yeast homologous recom-
bination. Replacement of the LEU2d marker for the 
URA3 marker was performed by cutting the plasmid 
once within the LEU2d marker, treatment of the plasmid 
with phosphatase, and co-transformation of the treated 
cut plasmid with PCR product of the URA3 cassette, 
with flanking ends homologous to the site of integration 
within the vector.
JBEI-10650. DNA from Y. Lipolytica was prepared 
using the modified Mini prep protocol described above. 
The pESC-LEU2d backbone, the Y.l.IDH1 and PGAL1/10 
fragments were amplified for Gibson assembly-based 
construction as described above. The genomic Y.l.IDH2 
gene contains an intron 24 base pairs 3′ from the start of 
the coding sequence. In order to remove the intron, the 
intron-less coding sequence was broken into two parts. 
The first part was amplified from a 500-bp gBlock (IDT), 
while the second part was amplified from genomic 
DNA.
ACL Activity assay
Cell lysates were prepared as follows: 20 OD units of 
three biological replicate cultures were centrifuged at 
3300×g for 10 min. Cells were washed in 2 mL of 0.1 M 
Tris buffer, pH 8.7 supplemented with 10  µL protease 
inhibitor (Sigma cat. no. P8215) and then resuspended in 
500 µL of the same buffer. 500 µL of glass beads (USA sci-
entific) were added, and cells were broken using a bench-
top homogenizer/bead beating instrument (FastPrep-24, 
MP Biomedicals). Cells were shaken 5 ×  20  s intervals, 
separated by one-minute intervals on ice. Beads and 
cellular debris were centrifuged at 10,000×g for 2  min 
at 4  °C. 300 µL of supernatant were collected as the cell 
lysate.
ACL activity assays were performed as described previ-
ously [26] with minor modifications. Briefly, 20 µL of cell 
lysate was added to a mixture composed of 100 mM Tris–
HCl (pH 8.4), 20 mM sodium citrate, 5 u/ml malate dehy-
drogenase (Sigma), 10 mM MgCl2, 10 mM DTT, 0.15 μM 
NADH, 0.3 mM Coenzyme A, and 5 mM ATP. Reactions 
were initiated by adding cell lysate and the decrease in 
absorption at 340 nm was monitored every 15 s using a 
SPMAX plate reader set at 30  °C. Lysate activities were 
calculated as the initial rate of the decrease in absorp-
tion at 340 nm. Initial rates were calculated as the slope 
of a general linearized model for the first 10 min of the 
reaction. For the ACL-containing strains, activities were 
reported as the absolute initial rate divided by the initial 
rate of the parent strain, then divided by total mg protein 
in each sample as measured by Pierce BCA protein assay 
kit (Life Technologies).
Citric acid cycle metabolite analysis
Metabolite extraction was performed as previously dem-
onstrated by [38], modified for S. cerevisiae by use of 
bead-beating for cell lysis of five OD units of culture. Tri-
carboxylic acid (TCA) cycle intermediates were analyzed 
by liquid chromatography and mass spectrometry (LC–
MS). Chemical standards were made up to 200 µM, as the 
stock solution, in methanol–water (50:50, v/v). The sepa-
ration of the TCA cycle intermediates was conducted on 
a ZIC-pHILIC column (150 mm length, 4.6-mm internal 
Table 2 Expression plasmids used in this study
Plasmid name JBEI registry number Description Reference
pESC-LEU JBEI-10738 Yeast episomal plasmid with 2μ-origin and LEU2 selectable marker Stratagene, La Jolla, CA
pACLab JBEI-7134 pESC-PGAL10-AnACLb-PGAL1-AnACLa-LEU2d This study
pESC-URA JBEI-10737 Yeast episomal plasmid with 2μ-origin and URA3 selectable marker Stratagene, La Jolla, CA
pMvaES JBEI-10632 pESC-PGAL10-EfMvaE-PGAL1-EfMvaS-URA3 This study
pYlIDH JBEI-10650 pESC-PGAL10-YlIDH1-PGAL1-YlIDH2-Leu2d This study
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diameter, and 5-µm particle size; from Merck SeQuant, 
and distributed via The Nest Group, Inc., MA., USA) 
using an Agilent Technologies 1200 Series HPLC system 
(Agilent Technologies, CA, USA). The sample injection 
volume was 3 µL. The temperature of the sample tray was 
maintained at 4 °C using an Agilent FC/ALS Thermostat. 
The column compartment was set to 40  °C. The mobile 
phase was composed of (A) 10 mM ammonium carbon-
ate and 0.5 % ammonium hydroxide in acetonitrile–water 
(2:8, v/v) and (B) 10 mM ammonium carbonate and 0.5 % 
ammonium hydroxide in acetonitrile–water (8:2, v/v). 
TCA cycle intermediates were eluted isocratically with a 
mobile phase composition of 33  % mobile phase A and 
67 % of mobile phase B. A flow rate of 0.45 mL/min was 
used. The HPLC system was coupled to an Agilent Tech-
nologies 6210 time-of-flight mass spectrometer (LC-TOF 
MS) by a 1/6 post-column split. Contact between both 
instrument set-ups was established using a LAN card in 
order to trigger the MS into operation upon initiation of 
a run cycle from the MassHunter workstation (Agilent 
Technologies, CA, USA). Electrospray ionization (ESI) 
was conducted in the negative ion mode and a capillary 
voltage of—3500 V was used. MS experiments were car-
ried out in full scan mode, at 0.86 spectra/second for the 
detection of [M–H]/Z. Prior to LC-TOF MS analysis, the 
TOF MS was calibrated via an ESI-L-low concentration 
tuning mix (Agilent Technologies, CA, USA). Data acqui-
sition and processing were performed by the MassHunter 
software package. The instrument was tuned for a range 
of 50–1700 m/z—were quantified via eight-point calibra-
tion curve ands ranging from 625 nM to 200 µM. The R2 
coefficients for the calibration curves were ≥0.99.
CoA metabolite analysis
For CoA metabolite analysis, a method previously estab-
lished was adapted from [7]. Briefly, 20 OD units of each 
culture were pelleted (6000 rpm, 5 min, 4 °C). The super-
natant was aspirated, and the cells were suspended in 
1 mL of 10 % TCA containing crotonyl-CoA (10 μM) as 
an internal standard. The cells were bead-beaten for a 
total of 5 min (intervals of 20 s of beating followed by 20 s 
on ice). The supernatant was collected and neutralized 
with 2 × volume of 1 M octylamine. Samples were then 
filtered and the neutralized TCA extract was analyzed via 
LC–MS using electrospray ionization. The LC conditions 
used were adapted from [31].
Extracellular metabolites and organic acids detection
Glucose, galactose, acetate, ethanol and glycerol were 
separated by HPLC and detected by RID and DAD detec-
tors. One mL of cell culture was transferred and centri-
fuged at 18,000×g for 5 min. The supernatant was then 
filtered using a Costar® Spin-X® Centrifuge Tube Filters, 
0.22-µm pore and applied to an Agilent 1100 series HPLC 
equipped with an Agilent 1200 series auto-sampler, an 
Aminex HPX-87H ion exchange column (Biorad), and an 
Agilent 1200 series DAD and RID detectors. Metabolites 
were separated using 4 mM H2SO4 aqueous solution with 
a flow rate of 0.6 ml/min at 50 °C. Galactose consumption 
was calculated as the concentration of galactose remain-
ing in prepared medium with cultured strains, subtracted 
from the concentration of galactose in the control culture 
of prepared media without cells.
Mevalonate and squalene quantification
A detailed description of mevalonate and squalene quan-
tification was recently described [36]. In brief, meva-
lonate was derivatized to mevalonolactone by mixing 
200  µL cell culture with 50  µL 2  M HCl and vortexing 
for 15  min. Mevalonolactone was extracted into ethyl 
acetate by adding 250 µL ethyl acetate containing 10 μg/
mL caryophyllene (internal standard) and vortexing for 
5  min. Samples were centrifuged at 3000×g for 5  min 
and 100 µL of the organic phase was removed and trans-
ferred to glass GC vials for GCMS analysis. 1 μL of sam-
ple was injected (splitless), by using He as the carrier gas 
onto a CycloSil-B column (Agilent, 30-m length, 0.25-
mm inner diameter (i. d.), 0.25-μm film thickness, cat. 
no. 112–6632) using an Agilent GC system 6890 series 
GCMS with Agilent mass selective detector 5973 net-
work. The carrier gas was held at a constant flow rate of 
1.0  mL/minutes. After each sample injection, the oven 
temperature was held at 90  °C for 1  min, followed by a 
ramp of 30  °C/minute to a final temperature of 250  °C, 
and then held at 250 °C for 2 min. Solvent delay was set 
to 3.5 min, EMV mode was set to a gain factor of 1, and 
the MS instrument was set to SIM for acquisition, moni-
toring m/z ions 58 and 71 (mevalonolactone ions), along 
with 189 and 204 (caryophyllene internal standard ions). 
Peak areas for mevalonolactone and caryophyllene were 
quantified using MSD Productivity ChemStation soft-
ware (Agilent), and relative mevalonolactone levels were 
calculated as the quotient of mevalonolactone and caryo-
phyllene. For absolute quantification, sample values were 
fit to a generalized linear model generated from mevalo-
nolactone standards.
Squalene was extracted by resuspending cells from 
2  mL culture in 0.4  mL of the alcoholic KOH solution 
containing 10 μg/mL cholesterol, and boiling for 5 min. 
Squalene was extracted from the alcoholic solution by 
adding 0.4 mL of dodecane and vortexing for 5 min. Sam-
ples were centrifuged at 3000×g for 5 min and 100 µL of 
the organic phase was removed to glass GC vials. GCMS 
analysis and quantification were as described above with 
the following modifications: samples were injected onto 
a DB-5MS column (Agilent); after each sample injection, 
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the oven temperature was held at 80  °C for 1  min, fol-
lowed by a ramp of 20  °C/min to 280  °C, and then held 
for 15  min at 280  °C and a ramp to 300  °C at a rate of 
20 °C/min with a final hold at 300 °C for 2 min.; solvent 
delay was set to 10 min, EMV mode was set to a gain fac-
tor of 1, the mass spectrometer was set to SIM acquisi-
tion mode, monitoring m/z ions 218, 386 and 396, and 
the temperatures of the quadrupole and the ion source 
were set to 200 and 300 °C, respectively.
Results
Activity of ACLs from different sources
Previous work has demonstrated that incorporating ACL 
from various organisms into S. cerevisiae improves pro-
duction of acetyl-CoA derived products [11, 24, 40]. We 
synthesized yeast codon optimized ACL genes from five 
different sources—four from the fungi A. nidulans, R. 
toruloides, Y. lipolytica, and L. starkeyii, and one from 
the house mouse Mus musculus. In order to compare 
the activity of the heterologously expressed ACLs, we 
integrated each of the sequences into the S. cerevisiae 
genome, and measured their activity in crude cell lysates 
using an NADH-dependent coupled assay (Fig.  2). We 
observed a range of activity levels among the cell lysates. 
ACLs from R. toruloides and L. starkeyi displayed no 
detectable activity, ACLs from Mus musculus and Y. lipo-
litica displayed activity above background, consistent 
with previous publications [11, 24, 40]. The ACL from 
A. nidulans exhibited the highest activity by approxi-
mately an order of magnitude. Because the ACL from A. 
nidulans exhibited by far the highest activity, we decided 
to focus on this enzyme to further characterize expres-
sion of this ACL in S. cerevisiae.
Engineering increased intracellular flux through ACL
In S. cerevisiae citrate is primarily produced in the mito-
chondrion, where it is consumed by the citric acid cycle. 
A fraction of the mitochondrial citrate is transported 
to the cytoplasm by the citrate transporter CTP1 in 
exchange for malate [21]. The cytoplasmic citrate may 
then be consumed by ACL for cytoplasmic acetyl-CoA 
production. To determine whether A. nidulans ACL is 
active in  vivo, and whether enough intracellular citrate 
is available for increased acetyl-CoA production, we 
measured the intracellular concentrations of citrate and 
acetyl-CoA in a strain containing A. nidulans ACL on 
a high copy plasmid. These strains were grown in both 
standard (i.e., supplemented to 1 g/L ammonium sulfate) 
and nitrogen limited conditions, as previous studies have 
reported higher activity of the mitochondrial citrate syn-
thase in cells grown with low nitrogen concentration [22]. 
Citrate levels decreased to a similar extent in both con-
ditions when ACL was expressed (39  % standard nitro-
gen; 35  % low nitrogen), suggesting that heterologously 
expressed ACL actively consumed citrate irrespective 
of nitrogen concentration (Fig. 3a). However, we indeed 
observed higher absolute levels of citrate in nitrogen-
limited conditions when compared with the wild-type 
strain grown in medium with standard nitrogen sup-
plementation (70  % increase) (Fig.  3a). The increase in 
total intracellular citrate concentrations associated with 
growth in limited nitrogen medium prompted us to 
adopt this growth condition for subsequent engineering 
experiments.
Surprisingly, the total cellular acetyl-CoA concentra-
tion decreased in both limited and standard nitrogen 
conditions with the expression of ACL (Fig. 3c). Because 
there are myriad cellular pathways that consume acetyl-
CoA [12], we reasoned that total acetyl-CoA levels may 
not reflect flux through ACL. Consistently, several previ-
ous studies have demonstrated that total cellular acetyl-
CoA concentrations between strains do not correlate 
with production of acetyl-CoA derived products [31, 39].
One of the major sinks for cytoplasmic acetyl-CoA in 
S. cerevisiae is the isoprenoid pathway, which leads to 
the biosynthesis of ubiquinone, prenylated proteins, and 
sterols (Fig.  1). Previous work has shown that strains 
engineered for isoprenoid production exhibit accumu-
lation of the pathway intermediate mevalonate [30, 36]. 
We observed an increase in mevalonate suggesting that 
ACL expression may increase flux toward the meva-
lonate pathway, however the effect was modest (30  %) 



























Organism sources of enzymes
Fig. 2 Activity measurements of heterologously expressed ACL from 
various organisms. Organisms are: An, Aspergillus nidulans; Mm, Mus 
musculus; Yl, Yarrowia lipolytica; Rt, Rhodosporidium toruloides; Ls, Lipo-
myces starkeyii. Respective strains are: An, JBEI-10683; Mm, JBEI-10685; 
Yl, JBEI-10686; Rt, JBEI-10684; Ls, JBEI-10687
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acetyl-CoA-dependent pathways was likely due to insuf-
ficient citrate supply.
In order to increase citrate supply to ACL, we 
attempted to further mimic the lipid accumulation 
phase of oleaginous yeast central carbon metabolism, 
by shunting the citrate destined for the TCA cycle to 
the cytoplasm. In oleaginous yeast, the major regula-
tory mechanism controlling the shift of citrate flux 
from the TCA cycle to ACL is mediated by inhibition of 
mitochondrial ICDH [9, 10]. S. cerevisiae contains both 
NADP+- and NAD+-dependent mitochondrial ICDHs. 
In a wild-type background the NAD+-dependent mito-
chondrial ICDH mediates the bulk of the cellular flux 
[6]. It has been shown previously that deletion of IDH1, 
which encodes the regulatory subunit of NAD+-depend-
ent mitochondrial ICDH, results in increased citrate 
concentration [25], suggesting that IDH1Δ could effec-
tively shunt citrate from the TCA cycle to the cytoplasm. 
This prompted us to measure the effect of IDH1Δ and 
ACL overexpression on the levels of other key central 
carbon metabolites.
Changes in metabolite concentrations in strains with 
IDH1Δ and ACL expression strongly suggest that we suc-
cessfully reconstituted this key aspect of oleaginous yeast 
metabolism. First, isocitrate was undetectable in IDH1+ 
strains, but was clearly detectable in the IDH1Δ back-
ground, indicating that flux through ICDH was effectively 
blocked (Fig.  3b). Second, while citrate and isocitrate 
concentrations increased in the IDH1Δ background, both 
decreased dramatically when ACL was expressed, indi-
cating that a substantial fraction of cellular citrate was 
transported from the mitochondrion to the cytoplasm 
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JBEI 10688 ( )
JBEI 10688 ( ) + pACLab
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Low [(NH4)2SO4]
Fig. 3 Intracellular concentrations of metabolites relevant to ACL activity as a function of nitrogen availability. Citrate (a), isocitrate (b), acetyl-CoA 
(c), mevalonate (d)
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and consumed by ACL (46 % decrease in citrate concen-
trations with ACL expression) (Fig.  3b, c). Third, while 
the mevalonate concentration decreased in the IDH1Δ 
background, it increased when ACL was expressed (96 % 
increase) (Fig. 3d), suggesting that shunting citrate from 
the TCA cycle may allow additional acetyl-CoA pro-
duced by ACL to be directed to acetyl-CoA dependent 
biosynthesis pathways.
Other key metabolites of the TCA cycle and glyoxy-
late shunt were measured (Additional file  2: Figure S1). 
IDH1∆-modified strains demonstrate fold increases of 
intracellular concentrations of malate, fumarate and 
succinate by 2.5, 2.2, and 1.8, respectively, as compared 
to the wild type strain (Additional file  2: Figure S1). 
Interestingly, these metabolites are key products of the 
glyoxylate cycle, and large increases in intracellular con-
centrations of malate, fumarate, and succinate in IDH1∆ 
strains may be indicative of utilization of the glyoxylate 
cycle. Notably, 2-oxoglutarate was also found to signifi-
cantly increase (205 % increase) with ACL expression, as 
compared to the IDH∆ background without ACL (Addi-
tional file 2: Figure S1). We speculate that the expression 
of ACL leads to down stream effects which replenish the 
mitochondria with 2-oxoglutarate for further oxidative 
phosphorylation.
Increasing pull on cytoplasmic acetyl‑CoA towards the 
mevalonate pathway
We next set out to test whether our strategy could be 
used to improve biosynthesis of acetyl-CoA  derived 
products in a strain engineered for greater pull towards 
the mevalonate pathway. In particular we focused on 
production of the acetyl-CoA derived pathway interme-
diate mevalonate, because of its potential use as a precur-
sor for biobased production of β-methyl-δ-valerolactone 
[42]. Acetyl-CoA flux was directed to the mevalonate 
pathway by integrating two genes from Enterococcus fae-
calis, mvaE and mvaS, that together encode the first three 
steps of the mevalonate pathway [17, 43, 44] (Fig.  1). 
Functional expression of these genes has not previously 
been demonstrated in S. cerevisiae to our knowledge.
When mvaE and mvaS were expressed in a wild-type 
background, we observed a significant increase in both 
mevalonate and the downstream metabolite squalene 
(Fig. 4a, b). Squalene has previously been shown to accu-
mulate in strains engineered for increased flux to the 
mevalonate pathway [8, 37]. Expressing ACL with mvaE 
and mvaS did not lead to an increase in mevalonate 
concentration, and led to only a  ~twofold increase in 
squalene concentration. However, when ACL, mvaE, 
and mvaS were expressed in an IDH1Δ background, we 
observed significant increases in both mevalonate and 
squalene (137 and 445 %, respectively, increase over the 
strain engineered with mvaE, and mvaS expression only). 
These data demonstrate that while expression of the 
upper mevalonate pathway genes mvaE and mvaS leads 
to mevalonate accumulation, a substantial amount of 
produced mevalonate is converted to downstream prod-
ucts such as squalene, and may also accumulate as other 
downstream products (Fig. 1). Lastly, the combined strat-
egy of ACL expression with IDH1Δ led to a  ~threefold 
increase in mevalonate production over strains without 
these two modifications. This is consistent with our pre-
vious results, and indicates that shunting citrate from the 
TCA cycle via IDH1Δ in combination with expression of 
ACL is a viable strategy for increasing flux to the meva-
lonate pathway.
Interestingly, the best producing strain (JBEI 10691–
IDH1Δ; ACL; mvaES) also exhibited substantially less 
growth than the IDH1+ strains (Additional file  3: Fig-
ure S2). We reasoned that this may have been caused 
by reduced citrate flux to the TCA cycle. We initially 
hypothesized that replacing S. cerevisiae ICDH with one 
from an oleaginous yeast might achieve a flux distribu-
tion between the TCA cycle and the ACL pathway that 
would allow for improved growth and similar or higher 
titers, as previous work has shown that ICDH from ole-
aginous yeast are responsive to the carbon/nitrogen 
molar ratio [43]. To test this, genes from Y. lipolytica with 
homology to S. cerevisiae IDH1 and IDH2 were iden-
tified, and their functionality was confirmed through 
complementation of S. cerevisiae IDH1/2Δ (Additional 
file 4: Figure S3). However, when the Y. lipolytica ICDH 
replaced IDH1, we observed reduced production com-
pared with IDH1Δ (Fig.  4). The failure of Y.l.IDH1/2 to 
improve mevalonate production is likely due to the dif-
ferent regulatory environment between oleaginous yeasts 
and S. cerevisiae.
Engineering a strain for high mevalonate production
Having demonstrated that expressing ACL in the IDH1Δ 
background serves to increase flux to the engineered 
mevalonate pathway, we next focused our efforts on fur-
ther increasing production of the pathway intermediate 
mevalonate. We first determined that mevalonate does 
not inhibit growth, nor is it consumed as a carbon source 
(Additional file 5: Figure S4 A, B). We then determined 
that mevalonate does not accumulate intracellularly, and 
is efficiently exported extracellularly (Additional file  6: 
Figure S5). To engineer mevalonate accumulation, mvaE 
and mvaS were expressed from a high copy plasmid so as 
to maximize flux from acetyl-CoA to mevalonate. Then, 
we attempted to reduce flux downstream of mevalonate 
by modifying the expression of mevalonate kinase, the 
next step in the mevalonate pathway. This activity is 
encoded by ERG12, which is essential, as flux through 
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the mevalonate pathway is necessary for production of 
sterols, lipids and a host of other metabolites (Fig.  1). 
In order to achieve an expression level that allowed 
enough flux through the mevalonate pathway to meet 
essential requirements, while limiting accumulation of 
other pathway intermediates, the ERG12 promoter was 
replaced with the copper-repressible CTR3 promoter. 
Consistent with our previous results, expression of ACL 
(without the PCTR3::PERG12 modification) resulted in 
an approximately twofold increase in mevalonate pro-
duction. When the PCTR3::PERG12 modification was 
introduced (without ACL expression), ERG12 repres-
sion resulted in a twofold increase in mevalonate pro-
duction. When the two modifications were combined, 
we observed a modest but significant increase in meva-
lonate production as compared to strains engineered 
with either of the individual modifications, ultimately 
leading to production of over 30 mg/liter of mevalonate 
(Fig. 5).
Conclusions
In this study the yeast S. cerevisiae was engineered 
with an alternative mode of acetyl-CoA biosynthe-
sis mediated by ACL in conjunction with a push/pull/
block strategy. As a proof of principle, we demonstrate 
that this alternative mode of metabolism can be used 
as a strategy to significantly increase the yield of the 
acetyl-CoA  derived product mevalonate. We demon-
strate the basic requirements for directing flux through 
the ACL pathway: increased citrate supply, expression 
of an active ACL, increased pull towards a product of 
interest, and limitation of competing downstream path-
ways. We anticipate that this strategy can be extended 






































JBEI 10692 (MvaES; ACLab;IDH-Yl)
Fig. 4 Time course of mevalonate production (a) and cellular squalene concentrations (b) in engineered strains. Strains are: No symbols represent the 
unengineered parent strain BY4741; Empty squares represent BY4741 with MvaES genes expressed, JBEI 10569; Emtpy circles represent BY4741 with 
MvaES and ACLab genes expressed, JBEI 10690; Filled circles represent BY4741 with MvaES and ACLab genes expressed, and the IDH1 gene deleted, 
JBEI 10691; Crosses represent BY4741 with MvaES, ACLab, and the Y. lipolitica IDH genes expressed JBEI 10692. Strains were grown in low [(NH4)2SO4]
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JBEI-10693 JBEI-10689 JBEI-10694Host strain
Fig. 5 Comparison of mevalonate production levels by engineered 
S. cerevisiae strains with and without the PCTR3::PERG12 promoter 
replacement, and strains with and without ACL, grown in various con-
centrations of CuSO4. All strains carry IDH1∆ and harbor the pMvaES 
plasmid. Strains were grown in low [(NH4)2SO4]
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to the production of a wide array of acetyl-CoA derived 
molecules.
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